Finally, a recent longitudinal randomized cross-over study in with safinamide (a potent and selective monoamine oxidase B (MAOB) inhibitor that enhances dopaminergic neurotransmission and inhibits glutamate release and dopamine and serotonin reuptake) involving 30 patients with PD and RBD showed a significant clinical improvement of RBD symptoms in more than 70% [57]. Here, MAOB is linked to Parkinson disease.